Brodalumab,一种靶向白细胞介素17受体A(IL-17RA)的人单克隆抗体,在美国和欧盟被批准用于治疗成人中度至重度斑块状银屑病。尽管brodalumab在银屑病和银屑病关节炎(PsA)患者的临床试验中证明了与安慰剂相比的疗效和安全性,需要真实世界的证据来评估brodalumab在常规护理中的长期有效性和安全性.德国牛皮癣登记处PsoBest的中期分析检查了患者资料,治疗结果,和首次使用Brodalumab治疗中度至重度斑块型银屑病(伴和不伴PsA)的成年患者12个月的药物存活率(数据截止时间:2021年6月30日)。临床医生和患者报告的总队列结局(n=227;PsA,n=38)表明在前3个月内对Brodalumab治疗有快速反应,维持了12个月。药物1年生存率为76.2%,平均停药时间为8.3个月.中止的原因主要是失去/缺乏效力,其次是不良事件,禁忌症和皮肤清除。总之,brodalumab在德国中重度银屑病和PsA患者中显示出快速和持续的有效性,并且在现实世界中具有良好的耐受性超过12个月。
Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although
brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profiles, treatment outcomes, and drug survival of first-time use of
brodalumab for 12 months in adult patients with moderate-to-severe plaque-type psoriasis (with and without PsA) (data cutoff: June 30, 2021). Clinician and patient-reported outcomes of the total cohort (n = 227; PsA, n = 38) indicated a rapid response to
brodalumab treatment within the first 3 months, which was maintained up to 12 months. The overall one-year drug survival rate was 76.2%, the mean time to discontinuation was 8.3 months. Reasons for discontinuation were mainly loss/lack of effectiveness, followed by adverse events, contraindication and skin clearance. In sum,
brodalumab demonstrated rapid and sustained effectiveness and was well-tolerated over 12 months in German patients with moderate-to-severe psoriasis and PsA in a real-world setting.